Australia · Delayed Price · Currency is AUD Monash IVF Group Earnings Call Transcripts
Fiscal Year 2026
-
Underlying NPAT reached AUD 10.4 million at the upper end of guidance, despite revenue and market share declines in domestic IVF. International and genetics segments showed growth, and margin recovery is targeted through price increases and operational efficiencies into FY 2027.
Fiscal Year 2025
-
Revenue and EBITDA grew in FY2025 despite sector headwinds and adverse incidents, with no final dividend declared. Board renewal and leadership transition are underway, and strategic investments continue, while competitive pressures and risk management remain key focus areas.
-
Underlying NPAT for FY2025 was AUD 27.4 million, with revenue up 7% and EBITDA up 5.6%, despite market share declines and industry headwinds. FY2026 guidance is for lower NPAT due to a 10% drop in new patient registrations, but mid-single-digit growth is expected to resume from FY2027.
-
Underlying NPAT grew 5.5% to AUD 15.8 million, with revenue up 12% and EBITDA margin steady at 25%. Market share gains, international growth, and cost optimization offset industry headwinds, supporting FY 2025 NPAT guidance of AUD 30–31 million.
Fiscal Year 2024
-
Record financial growth was achieved in FY2024, with strong contributions from all business segments and significant international expansion. The class action settlement impacted results and board refreshment, while strategic focus remains on Southeast Asia and emerging growth drivers.
-
Underlying NPAT reached AUD 29.9 million and revenue grew 19.4% year-over-year, despite a one-off class action settlement causing a net loss after tax. Market share, clinical outcomes, and international performance all improved, with strong growth expected in FY 2025.